DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus.
Newborn macaques were vaccinated against a chimeric simian human immunodeficiency (SHIV) virus, SHIV-vpu+, by DNA priming and boosting with homologous HIV-1 gp160. Following SHIV-vpu+ challenge, containment of infection was observed in 4 of 15 animals given DNA priming/protein boost vaccination and in three of four animals given gp160 boosts only. Rechallenge with homologous virus of six animals that contained the first challenge virus resulted in rapid viral clearance or low viral loads. Upon additional rechallenge with heterologous, pathogenic SHIV89.6P, four of these six animals maintained normal CD4+ T-cell counts with no or limited SHIV89.6P infection. Our data suggest that humoral and cellular immune mechanisms may have contributed to the containment of SHIV89.6P; however, viral interference with SHIV-vpu+ could also have played a role. Our results indicate that immunogenicity and efficacy of candidate AIDS vaccines are not affected when vaccination is initiated during infancy as compared with later in life.
Rasmussen
Robert A
RA
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Hofmann-Lehman
R
R
Montefiori
D C
DC
Li
P L
PL
Liska
V
V
Vlasak
J
J
Baba
T W
TW
Schmitz
J E
JE
Kuroda
M J
MJ
Robinson
H L
HL
McClure
H M
HM
Lu
S
S
Hu
S L
SL
Rizvi
T A
TA
Ruprecht
R M
RM
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000831:Animals, Newborn; D018791:CD4 Lymphocyte Count; D002678:Chimera; D004279:DNA, Viral; D006678:HIV / Q000276:immunology* / Q000472:pathogenicity; D007117:Immunization, Secondary / Q000662:veterinary; D008253:Macaca mulatta / Q000821:virology; D010957:Plasmids; D015302:Simian Immunodeficiency Virus / Q000276:immunology* / Q000472:pathogenicity; D014611:Vaccination / Q000662:veterinary
D016915:AIDS Vaccines; D004279:DNA, Viral